LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is expected to release its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect LENZ Therapeutics to post earnings of ($0.91) per share and revenue of $3.0880 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 4:00 PM ET.

LENZ Therapeutics Stock Down 2.9%

Shares of LENZ opened at $11.94 on Wednesday. The firm has a fifty day simple moving average of $15.25 and a two-hundred day simple moving average of $26.47. LENZ Therapeutics has a twelve month low of $11.21 and a twelve month high of $50.40. The stock has a market capitalization of $373.60 million, a P/E ratio of -5.66 and a beta of 0.52.

Hedge Funds Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in LENZ Therapeutics in the 4th quarter worth approximately $198,000. XTX Topco Ltd bought a new stake in shares of LENZ Therapeutics in the 4th quarter worth about $1,373,000. VARCOV Co. purchased a new stake in LENZ Therapeutics during the fourth quarter valued at approximately $1,261,000. Vestal Point Capital LP purchased a new stake in LENZ Therapeutics during the 4th quarter valued at $4,400,000. Finally, Virtus Investment Advisers LLC raised its stake in shares of LENZ Therapeutics by 879.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 37,674 shares of the company’s stock valued at $603,000 after acquiring an additional 33,827 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LENZ shares. William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday. Zacks Research cut LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Wall Street Zen raised shares of LENZ Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $56.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.